Friday, July 10, 2026

pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer

AstraZeneca

AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not ap

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
EMA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
249
Drugs
238
Patents
2
Clinical program

D9720C00003

Phase 2 · small molecule · Metastatic Prostate Cancer

D9720C00003 for Metastatic Prostate Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

← All AstraZeneca AB projects Phase 2 small molecule active

Internal code D9720C00003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AstraZeneca AB
Phase
Phase 2
Modality
small_molecule
Indication
Metastatic Prostate Cancer
Status
active
Trials
1